Table 1.
Baseline characteristics and blood tests of the study participants
| Characteristics | Values |
|---|---|
| Age (year), median (Q1-Q3) | 65 (59–70) |
| Male, n (%) | 487 (77.5) |
| Smoking, n (%) | 394 (62.7) |
| Biopsy bleeding, n (%) | 232 (36.9) |
| Location of lesion, n (%) | |
| Peripheral bronchi | 548 (87.3) |
| Central airway | 80 (12.7) |
| Stage, n (%) | |
| Early | 343 (54.6) |
| Advanced | 285 (45.4) |
| Histological types, n (%) | |
| Adenocarcinoma | 171 (27.2) |
| Squamous cell carcinoma | 313 (49.8) |
| SCLC | 111 (17.7) |
| Others | 33 (5.3) |
| Coexisting diseases, n (%) | |
| COPD | 42 (6.7) |
| Hypertension | 155 (24.7) |
| Diabetes | 32 (5.1) |
| CHD | 20 (3.2) |
| Blood tests, median (Q1-Q3) | |
| Triglyceride (mmol/L) | 1.0 (0.8–1.4) |
| TC (mmol/L) | 4.1 (3.5–4.8) |
| HDL-C (mmol/L) | 1.1 (0.9–1.3) |
| LDL-C (mmol/L) | 2.8 (2.3–3.3) |
| Apo E (mg/dL) | 3.6 (2.8–4.6) |
| Apo B (g/L) | 1.0 (0.8–1.2) |
| Homocysteine (μmol/L) | 13.2 (10.7–16.2) |
| WBC (× 109/L) | 6.8 (5.5–8.6) |
| Neutrophils (×109/L) | 4.6 (3.5–6.4) |
| Hemoglobin (g/L) | 128 (116–139) |
| Platelets (×109/L) | 224 (172–280) |
| CRP (mg/L) | 7.7 (1.4–31.1) |
| PT (S) | 13.0 (12.3–13.6) |
| APTT (S) | 35.1 (31.8–38.5) |
| ALT (IU/L) | 17.0 (12.0–25.0) |
| AST (IU/L) | 23.0 (19.0–28.0) |
SCLC Small-cell lung carcinoma; COPD Chronic obstructive pulmonary disease; CHD Coronary heart disease; TC Total cholesterol; HDL-C High density lipoprotein cholesterol; LDL-C Low density lipoprotein cholesterol; Apo, apolipoprotein; WBC White blood cell; CRP C-reactive protein; PT Prothrombin time; APTT Activated partial thromboplastin time; ALT Alanine aminotransferase; AST Aspartate aminotransferase